Akihiro Yoshimura

20PUBLICATIONS
60CO-AUTHORS
Molecular targetsPredictive and prognostic markersRespiratory diseasesLiquid biopsiesPlant pathology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 13, 2026
TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776-Altered Subtype of HER2-Mutant NSCLC.

|Jul 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto

|May 29, 2025
Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic Cancer.

Ema Toyokuni, Mano Horinaka, Emi Nishimoto

|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Kenji Morimoto

|Sep 14, 2024
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.

Haruka Kuno, Naoya Nishioka, Tadaaki Yamada

|May 31, 2024
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.

Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi

Pageof 4

Frequent Collaborators

13 joint publications

Tadaaki Yamada

9 joint publications

Koichi Takayama

7 joint publications

Takayuki Takeda

4 joint publications

Junji Uchino